Immuneering (NASDAQ:IMRX) Releases Earnings Results, Beats Expectations By $0.09 EPS

Immuneering (NASDAQ:IMRX) released its earnings results on Friday. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09, FiscalAI reports.

Immuneering Price Performance

NASDAQ IMRX traded up $0.02 during trading hours on Friday, hitting $5.16. 639,864 shares of the company’s stock traded hands, compared to its average volume of 1,332,904. Immuneering has a 52-week low of $1.29 and a 52-week high of $10.08. The company has a market capitalization of $333.85 million, a PE ratio of -3.74 and a beta of 0.37. The firm’s 50-day moving average is $5.35 and its 200-day moving average is $5.70.

Analyst Ratings Changes

Several analysts recently issued reports on IMRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research note on Monday, March 9th. Wall Street Zen raised shares of Immuneering from a “sell” rating to a “hold” rating in a research note on Sunday, April 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Institutional Trading of Immuneering

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in Immuneering in the first quarter valued at approximately $32,000. SummitTX Capital L.P. acquired a new stake in Immuneering during the fourth quarter worth $69,000. Mercer Global Advisors Inc. ADV purchased a new stake in Immuneering in the third quarter valued at $70,000. Ausdal Financial Partners Inc. purchased a new stake in Immuneering in the fourth quarter valued at $72,000. Finally, Moors & Cabot Inc. acquired a new position in shares of Immuneering in the 3rd quarter valued at $77,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.